This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Aclasta, AK-156, zoledronic acid
Description: Aclasta is a bisphosphonate that inihibits osteoclast-mediated bone resorption. It modulates bone metabolism by reducing bone turnover, improving bone mineralization, and increasing bone mass.
While the active ingredient of both Aclasta/Reclast and Zometa is zoledronic acid, Zometa comes in a 4mg dose given every 3-4 weeks and Aclasta/Reclast is given in a 5mg dose given once a year.
As of 2014, revenues are no longer reported for Aricept. As such, BioMedTracker no longer forecasts revenues.
Revenue splits for this drug are BioMedTracker estimates.
Novartis and Asahi Kasei
In June 2010, Asahi Kasei and Novartis announced a license agreement for zoledronic acid. Under the terms of the agreement, Asahi Kasei Pharma obtains exclusive rights in Japan to develop and sell zoledronic acid for the treatment of osteoporosis, and will begin clinical development of this agent in Japan.
Partners: Asahi Kasei Corporation
Additional information available to subscribers only: